Cargando…
lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2
Arsenic trioxide (As(2)O(3)) is a promising effective chemotherapeutic agent for cancer treatment; however, how and through what molecular mechanisms the oxidative damage of As(2)O(3) is controlled remains poorly understood. Recently, the involvement of dysregulated long noncoding RNA ovarian tumor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481943/ https://www.ncbi.nlm.nih.gov/pubmed/32952848 http://dx.doi.org/10.1155/2020/3035624 |
Sumario: | Arsenic trioxide (As(2)O(3)) is a promising effective chemotherapeutic agent for cancer treatment; however, how and through what molecular mechanisms the oxidative damage of As(2)O(3) is controlled remains poorly understood. Recently, the involvement of dysregulated long noncoding RNA ovarian tumor domain containing 6B antisense RNA1 (lncRNA OTUD6B-AS1) in tumorigenesis is established. Here, for the first time, we characterize the regulation of As(2)O(3) in the oxidative damage against bladder cancer via lncRNA OTUD6B-AS1. As(2)O(3) could activate lncRNA OTUD6B-AS1 transcription in bladder cancer cells, and these findings were validated in a xenograft tumor model. Functional assays showed that lncRNA OTUD6B-AS1 dramatically exacerbated As(2)O(3)-mediated oxidative damage by inducing oxidative stress. Mechanistically, As(2)O(3) increased levels of metal-regulatory transcription factor 1 (MTF1), which regulates lncRNA OTUD6B-AS1, in response to oxidative stress. Further, lncRNA OTUD6B-AS1 inhibited mitochondrial NADP(+)-dependent isocitrate dehydrogenase 2 (IDH2) expression by stabilizing miR-6734-5p, which contributed to cytotoxicity by enhancing oxidative stress. Together, our findings offer new insights into the mechanism of As(2)O(3)-induced oxidative damage and identify important factors in the pathway, As(2)O(3)/lncRNA OTUD6B-AS1/miR-6734-5p/IDH2, expanding the knowledge of activity of As(2)O(3) as cancer treatment. |
---|